Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
CALGB 80702
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
- NCT01150045 ↗
- Completed
- Alliance for Clinical Trials in Oncology
- Deep
We haven't built an HCP commentary report on CALGB 80702 (celecoxib, 5-fluorouracil and 2 more in Colorectal Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CALGB 80702 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 96 | |
| YouTube | 32 | |
| Podcasts | 15 | |
| Bluesky threads | 12 |
The trial
ClinicalTrials.gov- Official title
- A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Colorectal Cancer
- Interventions
- celecoxib; 5-fluorouracil; placebo; oxaliplatin; leucovorin
- Arms
- Arm A - FOLFOX and placebo (12 treatments) · Active comparator
- Arm B - FOLFOX and celecoxib (12 treatments) · Experimental
- Arm C - FOLFOX and placebo (6 treatments) · Active comparator
- Arm D - FOLFOX and celecoxib (6 treatments) · Experimental
- Enrollment
- 2,527
- Primary outcomes
- Disease-free Survival
- Sponsor
- Alliance for Clinical Trials in Oncology with National Cancer Institute (NCI)
- Start
- Jun 2010
- Primary completion
- Feb 28, 2020
- Results posted
- Yes
- Registry record
- NCT01150045 · updated May 19, 2026
Publications
linked from the registry- Lee S, Ma C, Shi Q, Kumar P, Couture F, Kuebler P, Krishnamurthi S, Tan B, Shergill A, O'Reilly EM, Shields AF, Meyerhardt JA. Flavonoids and survival in stage III colon cancer: CALGB/SWOG 80702 (alliance). JNCI Cancer Spectr. 2026 Oct 21:pkag112. doi: 10.1093/jncics/pkag112. Online ahead of print. PubMed 42902778
- Zhang GQ, Meyerhardt JA, Shi Q, Twombly T, Pederson L, Ma C, Vayrynen JP, Zhao M, Takashima Y, Shergill A, Kumar P, Couture F, Kuebler P, Krishnamurthi S, Tan B, O'Reilly EM, Giannakis M, Ogino S, Jurdi A, Sharma S, Aleshin A, Shields AF, Nowak JA. Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2026 Feb 1;12(2):149-158. doi: 10.1001/jamaoncol.2025.5144. PubMed 41343176
- Nowak JA, Twombly T, Ma C, Shi Q, Haruki K, Fujiyoshi K, Vayrynen J, Zhao M, Knight J, Mane S, Shergill A, Kumar P, Couture F, Kuebler P, Krishnamurthi S, Tan B, Philip P, O'Reilly EM, Shields AF, Ogino S, Fuchs CS, Meyerhardt JA. Improved Survival With Adjuvant Cyclooxygenase 2 Inhibition in PIK3CA-Activated Stage III Colon Cancer: CALGB/SWOG 80702 (Alliance). J Clin Oncol. 2024 Aug 20;42(24):2853-2859. doi: 10.1200/JCO.23.01680. Epub 2024 Jun 18. PubMed 38889377
- Lee S, Ma C, Shi Q, Meyers J, Kumar P, Couture F, Kuebler P, Krishnamurthi S, Lewis D, Tan B, O'Reilly EM, Shields AF, Meyerhardt JA. Sleep and cancer recurrence and survival in patients with resected Stage III colon cancer: findings from CALGB/SWOG 80702 (Alliance). Br J Cancer. 2023 Aug;129(2):283-290. doi: 10.1038/s41416-023-02290-2. Epub 2023 May 13. PubMed 37179438
- Cheng E, Shi Q, Shields AF, Nixon AB, Shergill AP, Ma C, Guthrie KA, Couture F, Kuebler P, Kumar P, Tan B, Krishnamurthi SS, Ng K, O'Reilly EM, Brown JC, Philip PA, Caan BJ, Cespedes Feliciano EM, Meyerhardt JA. Association of Inflammatory Biomarkers With Survival Among Patients With Stage III Colon Cancer. JAMA Oncol. 2023 Mar 1;9(3):404-413. doi: 10.1001/jamaoncol.2022.6911. PubMed 36701146
- Lee S, Ma C, Shi Q, Kumar P, Couture F, Kuebler P, Krishnamurthi S, Lewis D, Tan B, Goldberg RM, Venook A, Blanke C, O'Reilly EM, Shields AF, Meyerhardt JA. Potential Mediators of Oxaliplatin-Induced Peripheral Neuropathy From Adjuvant Therapy in Stage III Colon Cancer: Findings From CALGB (Alliance)/SWOG 80702. J Clin Oncol. 2023 Feb 10;41(5):1079-1091. doi: 10.1200/JCO.22.01637. Epub 2022 Nov 11. PubMed 36367997
- Gallois C, Shi Q, Meyers JP, Iveson T, Alberts SR, de Gramont A, Sobrero AF, Haller DG, Oki E, Shields AF, Goldberg RM, Kerr R, Lonardi S, Yothers G, Kelly C, Boukovinas I, Labianca R, Sinicrope FA, Souglakos I, Yoshino T, Meyerhardt JA, Andre T, Papamichael D, Taieb J. Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials. J Clin Oncol. 2023 Feb 1;41(4):803-815. doi: 10.1200/JCO.21.02726. Epub 2022 Oct 28. PubMed 36306483
- Meyerhardt JA, Shi Q, Fuchs CS, Meyer J, Niedzwiecki D, Zemla T, Kumthekar P, Guthrie KA, Couture F, Kuebler P, Bendell JC, Kumar P, Lewis D, Tan B, Bertagnolli M, Grothey A, Hochster HS, Goldberg RM, Venook A, Blanke C, O'Reilly EM, Shields AF. Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial. JAMA. 2021 Apr 6;325(13):1277-1286. doi: 10.1001/jama.2021.2454. PubMed 33821899